Digest Network How does it work
Network
/
Society
Te
Not verified

Teva Pharmaceutical Industries Ltd

What we write about

FinanceManagementMedical Health WellnessPharmaceuticalsWant ads

53 Press releases

View all press releases
30/05/2025
Pharmaceuticals
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
30/05/2025
Pharmaceuticals
Medical Health Wellness
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
29/05/2025
Pharmaceuticals
Medical Health Wellness
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
27/05/2025
Pharmaceuticals
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
27/05/2025
Pharmaceuticals
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
27/05/2025
Pharmaceuticals
Medical Health Wellness
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
22/05/2025
Pharmaceuticals
Finance
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
20/05/2025
Pharmaceuticals
Finance
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
20/05/2025
Pharmaceuticals
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0
19/05/2025
Pharmaceuticals
Finance
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Source
Teva Pharmaceutical Industries Ltd
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0